E
EBioscience
A wide range of antibodies, elisas, and proteins
About EBioscience
Established in 1999, eBioscience carved a significant niche in the life sciences sector by supplying critical reagents for immunology and oncology research. The company specialized in the development and provision of fluorochrome-conjugated antibodies, reagents for multicolor flow cytometry, highly-validated ELISA and multiplex immunoassay kits, and recombinant proteins. This product portfolio served researchers in academic institutions, as well as biotechnology and pharmaceutical companies, enabling detailed analysis of biological systems at the cellular level.
The firm's core business centered on manufacturing and selling a comprehensive catalog of research-use-only products. Its offerings supported a wide array of applications, including cancer research, epigenetics, neuroscience, and stem cell biology. A key part of its commercial strategy involved providing not just off-the-shelf products but also custom services, such as bulk reagent production and contract assay development, which offered tailored solutions for specific research needs.
eBioscience underwent significant corporate transitions, reflecting its value and strategic importance in the market. In October 2009, it acquired Bender MedSystems. A major milestone occurred on November 30, 2011, when Affymetrix acquired eBioscience for approximately $315 million. This integration was short-lived, as Thermo Fisher Scientific later acquired Affymetrix in a deal announced in January 2016 for about $1.3 billion, thereby incorporating the eBioscience portfolio into its Life Sciences Solutions Segment. This final acquisition aimed to expand Thermo Fisher's offerings in the rapidly growing flow cytometry market and strengthen its overall leadership in biosciences.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2009
- Headquarters
- San Diego, United States
- Employees
- 39
- Open positions
- None listed
- Dealroom signal
- 30.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Nov 2011 | $315M | $315M | Affymetrix | — |
| LATE VCOther financing | Feb 2011 | $55M | $220M | GE Capital | — |
Growth signals
Latest recorded traffic for EBioscience is 290 monthly website visits, up 26.1% over the last three months. EBioscience's team declined 32.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
GE Capital
Other known investors1 additional known investor
Affymetrix
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about EBioscience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EBioscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.